These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 8772646

  • 1. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
    de Klerk JM, Zonnenberg BA, Krouwer HG, Blijham GH, van Dijk A, van het Schip AD, van Die J, van Rijk PP.
    J Nucl Med; 1996 Mar; 37(3):465-7. PubMed ID: 8772646
    [Abstract] [Full Text] [Related]

  • 2. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
    de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Quirijnen JM, Blijham GH, van Rijk PP.
    J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
    [Abstract] [Full Text] [Related]

  • 3. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
    de Klerk JM, van Dieren EB, van het Schip AD, Hoekstra A, Zonnenberg BA, van Dijk A, Rutgers DH, Blijham GH, van Rijk PP.
    J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations.
    de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Stokkel MP, Han SH, Blijham GH, van Rijk PP.
    J Nucl Med; 1994 Sep; 35(9):1423-8. PubMed ID: 8071686
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
    Kolesnikov-Gauthier H, Carpentier P, Depreux P, Vennin P, Caty A, Sulman C.
    J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
    [Abstract] [Full Text] [Related]

  • 6. Dosage and response in radiopharmaceutical therapy of painful osseous metastases.
    Silberstein EB.
    J Nucl Med; 1996 Feb; 37(2):249-52. PubMed ID: 8667054
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
    de Klerk JM, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP.
    J Nucl Med; 1992 May; 33(5):646-51. PubMed ID: 1373767
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
    de Klerk JM, Zonnenberg BA, van het Schip AD, van Dijk A, Han SH, Quirijnen JM, Blijham GH, van Rijk PP.
    Eur J Nucl Med; 1994 Oct; 21(10):1114-20. PubMed ID: 7530199
    [Abstract] [Full Text] [Related]

  • 11. [Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
    Klutmann S, Bohuslavizki KH.
    MMW Fortschr Med; 1999 Nov 04; 141(44):38-9. PubMed ID: 10912142
    [Abstract] [Full Text] [Related]

  • 12. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F, Herberg A, Spadaro P, Restifo Pecorella G, Baldari S, Aricò D, Altavilla G, Baldari S.
    Q J Nucl Med Mol Imaging; 2006 Dec 04; 50(4):355-62. PubMed ID: 17043634
    [Abstract] [Full Text] [Related]

  • 13. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
    Han SH, De Klerk JM, Zonnenberg BA, Tan S, Van Rijk PP.
    Q J Nucl Med; 2001 Mar 04; 45(1):84-90. PubMed ID: 11456380
    [Abstract] [Full Text] [Related]

  • 14. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.
    Maxon HR, Schroder LE, Thomas SR, Hertzberg VS, Deutsch EA, Scher HI, Samaratunga RC, Libson KF, Williams CC, Moulton JS.
    Radiology; 1990 Jul 04; 176(1):155-9. PubMed ID: 1693784
    [Abstract] [Full Text] [Related]

  • 15. [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
    Róka R, Séra T, Pajor L, Thurzó L, Láng J, Csernay L, Pávics L.
    Orv Hetil; 2000 May 07; 141(19):1019-23. PubMed ID: 10846424
    [Abstract] [Full Text] [Related]

  • 16. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
    Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF, Guhlke S, Biersack HJ.
    J Clin Oncol; 2003 Aug 01; 21(15):2869-75. PubMed ID: 12885803
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain.
    Quirijnen JM, Han SH, Zonnenberg BA, de Klerk JM, van het Schip AD, van Dijk A, ten Kroode HF, Blijham GH, van Rijk PP.
    J Nucl Med; 1996 Sep 01; 37(9):1511-5. PubMed ID: 8790203
    [Abstract] [Full Text] [Related]

  • 18. Application of rhenium-188 HEDP in bone metastases therapy.
    Scheffler J, Derejko M, Bandurski T, Romanowicz G.
    Nucl Med Rev Cent East Eur; 2003 Sep 01; 6(1):55-7. PubMed ID: 14600935
    [Abstract] [Full Text] [Related]

  • 19. Palliative therapy with rhenium-186-HEDP for bone metastases of breast cancer.
    Guerra UP, Englaro E, Cattaruzzi E.
    Tumori; 1997 Sep 01; 83(2):560-2. PubMed ID: 9226021
    [No Abstract] [Full Text] [Related]

  • 20. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K, Hliscs R, Kropp J, Runge R, Knapp FF, Franke WG.
    J Nucl Med; 2003 Jun 01; 44(6):953-60. PubMed ID: 12791825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.